Midathetic

Quick links to important sections

Midathetic

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Midathetic

What is Midathetic?

Midathetic is a pharmaceutical medication developed to assist in the management of specific neurological or physiological conditions. It belongs to a class of compounds designed to interact with targeted pathways in the body to achieve a therapeutic effect.

Primary Function

The medication is primarily utilized to address symptoms associated with its indicated conditions. By modulating specific biological processes, Midathetic aims to stabilize or improve the patient's current health status. It is typically considered when standard first-line interventions require additional support or when a specific pharmacological profile is necessary for the patient's care plan.

Mechanism of Action

Midathetic works by influencing biochemical signals within the body. While the exact experience can vary between individuals, the underlying goal of the treatment is to provide a consistent therapeutic level that helps manage the progression or manifestation of symptoms. This involves the binding of the active ingredients to specific receptors, which helps regulate the physiological responses related to the condition being treated.

Clinical Context

Midathetic is administered as part of a comprehensive management strategy. Healthcare professionals evaluate the suitability of this medication based on an individual's medical history, the severity of their symptoms, and their overall health profile. It is intended to function as a component of a broader approach to health and wellness under professional supervision.

Regulatory References

  1. WHO Model List of Essential Medicines (current list)

What side effects are possible with Midathetic?

Possible Side Effects and Safety Information

The official safety profile for Midathetic (Midazolam) establishes that its primary documented risks are related to its function as a powerful Central Nervous System depressant, which structures the classification of its adverse reactions across several body systems.

Documented Adverse Reactions

Adverse effects are categorized by frequency, with the most serious involving cardiorespiratory function. Most Common regulatory classifications include decreased tidal volume, decreased respiratory rate, and apnea. Common reactions often listed include respiratory depression, hypoxia (low oxygen levels), hypotension (low blood pressure), and prolonged CNS effects such as oversedation, drowsiness, headache, nausea, and vomiting.

System-organ class groupings in regulatory labeling emphasize Respiratory, Thoracic, and Mediastinal Disorders (e.g., respiratory arrest, hypoventilation) and Nervous System Disorders (e.g., anterograde amnesia, dizziness, paradoxical reactions, and the potential for seizures).

Serious Safety Considerations

The most serious adverse reactions explicitly documented in official sources include respiratory arrest, cardiac arrest, and hypoxemic encephalopathy (brain damage due to lack of oxygen). The potential for physical dependence and withdrawal syndrome is associated with long-term use (e.g., several days to weeks).

Safety statements define increased risk for specific groups. Older adults have a documented increased sensitivity, leading to a higher danger of severe cardiorespiratory events. Neonates and Infants have an elevated risk of severe hypotension and withdrawal syndrome with prolonged use. Furthermore, concomitant use with other CNS depressants, such as opioids, is formally documented to increase the risk of profound sedation, respiratory depression, coma, and death.

Overdose and Emergency Response

Overdose and when to seek help — Official Regulatory Information for Midathetic

Overdose with Midathetic (Midazolam) is defined in regulatory documents as an exaggeration of its core pharmacological effects, which primarily affects the central nervous system (CNS) and cardiorespiratory function.

Overdose Scope

Property Official Regulatory Statement for Overdose
Documented Overdose Presentations Exaggerated CNS depression, including somnolence, confusion, slurred speech, and depressed reflexes.
Physiological Systems Affected CNS, Respiratory system (risk of apnea, hypoventilation), and Cardiovascular system (risk of hypotension, cardiac arrest).
Population-Specific Overdose Notes Elderly patients and individuals with compromised respiratory, hepatic, or renal function face an increased risk of severe and prolonged manifestations.
When Immediate Medical Help is Required Seek immediate medical attention or contact emergency services immediately if overdose symptoms occur, particularly if the patient experiences trouble breathing, apnea, or coma.

Resulting Overdose Structure

Official Overdose Statements:

  • Severe overdose may progress to coma, life-threatening respiratory arrest, and cardiac arrest.
  • The management of overdose involves symptomatic and supportive treatment, ensuring a patent airway, and utilizing the specific antagonist Flumazenil where clinically indicated.
  • Continuous monitoring of cardiorespiratory function and vital signs is required throughout the observation period to manage potential complications.

Connection to the overall overdose profile:

Regulatory documents define the overdose profile by emphasizing the progression from profound CNS depression to critical cardiorespiratory events. This mandates that regulatory authorities require immediate medical intervention and structured, supportive hospital management, including continuous monitoring and the availability of the specific reversal agent. These requirements are consistently highlighted for patients with identified population-specific risks.

Therapeutic Uses of Midathetic

What Midathetic Treats: Main Uses and Benefits

Midathetic (Midazolam) is used for short-term symptomatic support across critical acute and procedural contexts where assistance with patient awareness during acute phases and central nervous system activity is generally needed. This medication is commonly used to help with certain distressing symptoms related to heightened physiological activity.


Procedural and Preoperative Comfort

This medication helps address situational anxiety and apprehension patients may experience before or during diagnostic, endoscopic, or minor surgical interventions. It is applied in clinical settings marked by heightened patient distress to induce a state of calmness and lessened recollection of the event. This action offers supportive therapeutic benefit by helping ease the overall symptom burden of discomfort and may support a more manageable experience during the procedure.

Emergency Management of Acute Seizures

Midathetic is considered relevant for managing prolonged convulsive activity (seizures), such as Status Epilepticus or repetitive seizure clusters. It is applied in emergency situations requiring short-term symptomatic support and is applied in addressing convulsive activity. This symptomatic relief is crucial for supporting the patient during a difficult phase and assisting with the symptomatic manifestations associated with sustained hyperexcitability.

Sedation for Critically Ill Patients

This medication is generally applied in contexts involving heightened systemic burden, such as in critical care units. It plays a role in managing agitation and restlessness in patients, particularly those requiring mechanical ventilation. It is relevant when symptoms interfere with functional stability, supports patient comfort and contributes to easing the overall symptom load.

Quick Fact: Relief for Acute Anxiety and Convulsive Symptoms

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Midathetic (Midazolam) eligibility is strictly defined by regulatory guidelines based on a patient’s medical history, age, and physiological status. Certain conditions represent absolute non-eligibility and prohibit the use of the medicine.

Absolute Contraindications

Status Non-Eligible Populations
Contraindicated Known hypersensitivity to midazolam
Contraindicated Patients with acute narrow-angle glaucoma

Restricted and Conditional Use

Beyond absolute contraindications, specific populations are only eligible under restricted or conditional use as stated in the label. Eligibility is constrained by age, where use in pediatric patients less than 6 months of age for conscious sedation is not recommended. Elderly patients (typically ge 60 years) and debilitated patients are eligible, but require significantly reduced initial doses compared to healthy adults.

Use is also conditional upon organ function: caution is necessary for patients with impaired hepatic or renal function, as drug elimination may be delayed, prolonging effects. Similarly, patients with COPD or pre-existing respiratory insufficiency are at greater risk and require restricted use. For pregnancy and breastfeeding, use is conditional, and generally recommended only when the clinical benefit outweighs the potential risk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Regulatory documents define the interaction profile of Midathetic (Midazolam) based on its metabolism and its central nervous system (CNS) effects. This results in two primary classifications of interaction constraints: pharmacokinetic and pharmacodynamic.


Pharmacokinetic Interactions

Midathetic is primarily metabolized by the Cytochrome P450 3A4 (CYP3A4) enzyme system. Co-administration with CYP3A4 inhibitors (e.g., strong antifungals like Ketoconazole and certain antivirals like Ritonavir) can significantly decrease plasma clearance, leading to increased drug exposure and prolonged effect. Conversely, co-administration with CYP3A4 inducers (e.g., Rifampin or the herbal product St John's Wort) can cause a markedly decreased Cmax and AUC, resulting in reduced effectiveness. For oral administration, combination with strong CYP3A4 inhibitors is often contraindicated.


Pharmacodynamic and Substance Interactions

Combining Midathetic with other CNS depressants, such as Opioid Analgesics or Alcohol, carries a high risk of additive effects, increasing the potential for profound sedation, respiratory depression, and severe complications. This risk is noted to be greater in elderly or debilitated patients. Additionally, Grapefruit Juice is documented to reduce Midathetic's clearance. Regulatory labels impose specific timing restrictions for certain co-administered drugs, such as Lonafarnib, requiring mandated separation periods.

Mechanism of Action

How Midathetic Works

Midathetic exerts its pharmacodynamic effect by acting as a highly selective, small-molecule inhibitor of the cathepsin K enzyme . This lysosomal cysteine protease is predominantly expressed and active within osteoclasts. The drug binds directly to the enzyme’s active site, thereby preventing cathepsin K from performing its proteolytic function, specifically the degradation of the Type I collagen and other non-collagenous proteins that constitute the mineralized bone matrix.

This targeted inhibition arrests the enzymatic process required by the osteoclast for bone dissolution (resorption). The resulting suppression of cathepsin K activity leads to a decrease in overall osteoclast function and a reduction in the volume of bone resorbed. The system-level physiological consequence of this mechanism is the modulation of bone remodeling towards a decreased rate of bone mineral density loss through the specific reduction of resorption activity.

Dosage and Administration Information

How Midathetic is used: Official Administration Guidelines

The administration of Midathetic (Midazolam) is a highly regulated procedure, always requiring slow titration and continuous professional monitoring due to its potent, short-acting effects. The usage protocols are strictly defined in official clinical guidelines.


Approved Routes and Dosing Ranges

Midathetic is available in multiple forms to support specific administration routes in controlled settings:

  • Intravenous (IV) Injection/Infusion: The primary route for procedural sedation and critical care. Initial IV doses for a healthy adult under 60 typically range from 1 mg to 2.5 mg.
  • Intramuscular (IM) Injection: Used for preoperative sedation or, at a single 10 mg dose, for the acute management of Status Epilepticus in adults.
  • Intranasal or Oromucosal Solutions: Used for the acute treatment of seizure clusters, with a maximum frequency of one episode every three days and no more than five episodes per month.

Administration and Procedural Rules

Midazolam must never be administered by rapid injection. This medicine should be used only in settings equipped with resuscitation facilities and personnel trained in airway management, as specified in clinical labeling.

  • Titration Principle: Initial IV doses and subsequent increments must be given slowly, over at least 2 minutes. An additional 2 or more minutes must pass before repeating a dose to fully assess the effect.
  • Preparation: The 5 mg/mL injection may be diluted to 1 mg/mL to help achieve the slow, controlled rate of injection required for safe use.
  • Population Adjustments: Dosing must be reduced in specific groups. Older adults (over 60), debilitated patients, or those with renal or hepatic impairment require lower initial IV doses, sometimes starting at 0.5 mg to 1 mg. Pediatric sedation doses are calculated on a mg/kg basis.
  • Duration: For acute procedures, use is for a single event. For long-term continuous infusion in critical care, the dose must be gradually tapered upon discontinuation.

Recent Clinical Evidence

Research evidence / Overview of studies for Midathetic


Evidence for Use in Procedural and Preoperative Sedation

Midathetic was studied for its use in managing anxiety and exploring the outcomes related to sedation experienced by patients before or during brief medical procedures. Research primarily includes Randomized Controlled Trials (RCTs) and systematic reviews, which examined how Midathetic affects the level of sedation (drowsiness) and the degree of anxiolysis (anxiety relief). Studies reported measurements related to the time intervals measured for patients to become calm and how the level of comfort was measured during the procedure. Research also focused on the outcome of amnesia, where patients reported lessened recollection of the time during the procedure.

However, the evidence quality varies across studies, and systematic reviews noted that findings were mixed when comparing the measured outcomes against certain other sedative medications. Follow-up durations were limited in this area, and long-term effects are not fully established following procedural use.


Evidence for Use in Emergency Management of Acute Seizures

Midathetic was evaluated in research exploring outcomes related to the management of conditions associated with acute or disruptive episodes, specifically prolonged convulsive activity (seizures). These studies research examined outcomes such as the achievement of the study outcome of seizure cessation and the time required to achieve that cessation. Findings indicate that for seizure cessation, Midathetic's reported measurements appear to be similar to the reported measurements for other first-line benzodiazepine medications. The research base largely focuses on study outcomes measured in the minutes and hours immediately following administration, and long-term effects are not fully established beyond the immediate management phase.


Evidence for Use in Sedation for Critically Ill Patients

Midathetic use in studies was associated with measurements showing a longer duration of mechanical ventilation, and research reports an association with the incidence of delirium when compared to certain non-benzodiazepine agents. Studies observed that the compound accumulated in the body during prolonged infusions. The measured time required for patient awakening (extubation) following cessation of continuous infusion may be less predictable due to this accumulation. Long-term effects are not fully established concerning post-ICU quality of life or functional recovery outcomes. Limited data are available from small studies or observational sources exploring Midathetic use in certain complex patient groups.


Evidence Gaps and Areas of Uncertainty

Midathetic's research base contributes to the existing evidence landscape, but evidence highlights what is known — and what is still uncertain. Major research limitations include the fact that follow-up durations were limited for procedural and acute seizure uses, meaning that long-term effects are not fully established in these areas. Additionally, evidence quality varies across studies, and many research findings describe group patterns, not personal outcomes. There remains a need for more comprehensive, long-term studies.

Frequently Asked Questions (FAQ)

Common questions about Midathetic (FAQ)

Q: Why do people say Midathetic is different from other similar medicines?

Official documents classify Midathetic as a short-acting benzodiazepine. Medical literature suggests this classification is due to its rapid onset of action and relatively short duration compared to some other medications in the same class. These characteristics may be highlighted when describing its use for brief procedures.

Q: Can Midathetic be used in children?

The medicine can be used in pediatric patients, but dosing is specific to the patient, often based on body weight. Regulatory information specifies that rapid intravenous injection is not recommended in neonates (newborn infants).

Q: Is Midathetic safe for older adults?

According to official warnings, older adults (generally over 60 years) are noted to require lower initial doses than younger adults. This is due to a documented increased sensitivity and a higher risk of adverse effects related to breathing or heart function.

Q: Can people with kidney problems use Midathetic?

Official guidance states that use requires caution in patients with impaired kidney function. This is because the medicine's removal from the body may be slowed, which can potentially prolong its effects.

Q: Is Midathetic safe for people with liver disease?

Similarly, caution is necessary for patients with liver impairment. The way the medicine is processed by the body (metabolism) may be slowed, leading to a prolonged duration of its effects.

Q: Can Midathetic be taken if I am pregnant?

Official warnings state the medicine is known to cross the placenta. Use during later stages of pregnancy may be associated with problems for the newborn, such as temporary sedation or withdrawal symptoms.

Q: Is it okay to use Midathetic while breastfeeding?

The medicine has been detected in human milk. Any decision regarding its use while breastfeeding is made by the prescribing healthcare professional after carefully considering the potential risks and benefits.

Q: Are there any specific vitamins or supplements that interact with Midathetic?

Official drug information lists certain supplements, including St. John's wort, valerian, melatonin, and green tea, as having the potential to interact. These potential interactions are important to review with a healthcare professional.

Q: Do studies show that Midathetic is effective?

Research evidence has examined the medicine's ability to achieve specific clinical outcomes. These include achieving the desired level of sedation, providing anxiety relief (anxiolysis), and stopping acute seizure activity in approved uses.

Q: If I feel better, can I just stop taking Midathetic?

Discontinuation is typically managed by a healthcare professional, as official documents indicate that abrupt cessation following extended or continuous use may be associated with symptoms of physical dependence and withdrawal. If the medicine was taken continuously, a gradual reduction or taper may be required.

Q: How should I store Midathetic tablets?

The product should be stored securely in its original container and protected from light. Storage guidelines require it to be kept at controlled room temperature, out of the sight and reach of children.

Q: Is it true that Midathetic is only for short-term use?

While the medicine is classified as a short-acting agent suitable for single events (like procedural sedation), it is also approved for use as a continuous infusion protocol lasting for extended periods in critical care settings. Its use depends entirely on the clinical need.

Q: Can I take Midathetic with herbal remedies?

Yes, the potential for interaction exists with certain herbal products. Remedies such as St. John's wort are known to affect the medicine's metabolic pathway, and combining them requires professional medical consultation.

Q: How can I tell if Midathetic is working for me?

Studies indicate that the desired therapeutic effects are reduced anxiety (anxiolysis), a state of controlled drowsiness (sedation), and lessened recollection of the time during the procedure (amnesia). These are the expected outcomes when the medicine is used for approved indications.

Q: What does the patient leaflet say about allergic reactions to Midathetic?

The patient information advises immediately reporting signs of a hypersensitivity or allergic reaction. These symptoms may include a skin rash or hives, swelling of the face, lips, tongue, or throat, or trouble breathing.

Q: What are the restrictions for people with a history of seizures and Midathetic?

The medicine is approved for the management of acute, prolonged seizures. However, regulatory documents also list seizures or seizure-like activity as a possible nervous system adverse reaction in the safety profile.

Q: Why is the mechanism of Midathetic sometimes described as 'complex'?

Medical literature describes the medicine's action as enhancing the effect of the primary inhibitory neurotransmitter in the brain, called GABA. This highly selective and potent action is responsible for slowing down excessive nerve activity and producing the sedative effect.

Q: What is the average duration of treatment with Midathetic?

The duration of treatment depends entirely on the clinical purpose. Treatment can range from a single event for brief procedures (procedural sedation) to a continuous infusion protocol lasting for an extended period in critical care settings.

Q: What are the legal age restrictions for prescribing Midathetic?

Use for conscious sedation in pediatric patients less than 6 months of age is generally not recommended in official guidelines. Separately, dose reductions are required for older adults (over 60 years) due to age-related sensitivity.

Q: How is Midathetic eliminated from the body?

Official documents state the medicine is primarily processed by the Cytochrome P450 3A4 ( CYP3A4) enzyme system in the liver. It is noted to have a relatively short elimination half-life of approximately 3 hours in healthy adults.

Q: How long does it take for Midathetic to start working?

For intravenous administration, clinical reports typically describe the onset of the medicine’s sedative effects as occurring rapidly, within 1 to 2 minutes.

Q: How long do the effects of Midathetic last after I take it?

The duration of the desired effect is generally described in clinical reports as being between 15 and 80 minutes. This range depends on the administered dose and the specific route of administration chosen by the professional.

Q: Can Midathetic affect my ability to drive or operate machinery?

Official patient information states the medicine may cause drowsiness, difficulty with concentration, and trouble controlling movements. For this reason, official guidance states that operating hazardous machinery should be avoided until the effects of the medicine are fully known.

Q: Does Midathetic interact with common over-the-counter pain relievers?

The product is known to interact with other central nervous system ( CNS) depressants. This category can include certain over-the-counter medications like antihistamines and some cold and flu remedies, and any potential combination should be reviewed with a professional.

Q: What should I do if I notice a change in my heart rate after taking Midathetic?

Changes in heart rate (like a slow or increased heart rate) are noted in the safety profile. If severe cardiac symptoms occur or if you experience changes in breathing, seeking immediate medical attention is necessary.

Q: Is Midathetic known to cause weight gain or loss?

The official safety documents do not list common weight changes. However, rapid weight gain is noted in some adverse reaction reports as a less common possible side effect.

Q: Are there any known food restrictions with Midathetic besides grapefruit?

Regulatory documents specifically name grapefruit juice as a food restriction because it can affect how the medicine is processed. The main additional constraint is alcohol, due to the potential for severe additive central nervous system depressant effects.

Q: What happens if I take more Midathetic than prescribed?

Official labeling states that taking more than prescribed can result in overdose symptoms. These may include irregular or shallow breathing, confusion, loss of consciousness, lack of coordination, and severe dizziness.

Q: Is Midathetic available as a generic drug?

Yes, the active ingredient, midazolam, is widely available in generic formulations for injection and other routes of administration.

Q: Does Midathetic have a 'black box warning' in the US?

Yes, the US FDA Prescribing Information includes a Boxed Warning. This warning highlights the risks of severe respiratory depression and respiratory arrest, and the dangers of combining the medicine with opioid medications.

Q: How soon after stopping Midathetic will it be completely out of my system?

The elimination half-life is typically around 3 hours in healthy adults. It generally takes several half-lives for the medicine to be completely eliminated from the body.

Q: Is Midathetic a controlled substance?

Yes, the medicine's active ingredient, midazolam, is classified by the US Drug Enforcement Administration ( DEA) as a Schedule IV controlled substance. This classification is due to its accepted medical use and lower potential for abuse relative to Schedule III.

How should Midathetic be stored and disposed of?

How to Store and Dispose of Midathetic?

Storage and disposal of Midathetic (Midazolam) must strictly follow the requirements specified in the official regulatory labeling to ensure product stability and safety.

Official Storage Conditions

The product must be stored at controlled room temperature, typically 20 C to 25 C (68 F to 77 F), with protection from light. It is essential not to freeze the medication. Midathetic should remain in its original container, kept tightly closed, and stored securely out of the reach and sight of children.

Disposal Requirements

Disposal of unused or expired product must align with local and national regulations for pharmaceutical waste. The preferred method is returning the medicine via an approved drug take-back program. For specific oral liquid formulations, official guidance may direct immediate flushing down a toilet if a take-back program is unavailable, to mitigate the risk of accidental exposure.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Midathetic found in:

A-Z Index: